Brookline Capital Markets Estimates HURA Q2 Earnings

TuHURA Biosciences, Inc. (NASDAQ:HURA) – Analysts at Brookline Capital Markets lowered their Q2 2026 earnings per share (EPS) estimates for TuHURA Biosciences in a note issued to investors on Wednesday, May 27th. Brookline Capital Markets analyst K. Raja now expects that the company will earn ($0.13) per share for the quarter, down from their previous estimate of ($0.09). The consensus estimate for TuHURA Biosciences’ current full-year earnings is ($0.56) per share. Brookline Capital Markets also issued estimates for TuHURA Biosciences’ Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.52) EPS, FY2028 earnings at ($0.47) EPS and FY2029 earnings at $0.01 EPS.

A number of other research analysts have also commented on the company. Citizens Jmp started coverage on TuHURA Biosciences in a research note on Monday, April 27th. They issued a “market outperform” rating and a $9.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Tuesday, April 21st. Rodman & Renshaw started coverage on TuHURA Biosciences in a research note on Wednesday, April 15th. They issued a “buy” rating for the company. Citigroup started coverage on TuHURA Biosciences in a research note on Monday, April 27th. They issued an “outperform” rating for the company. Finally, Wall Street Zen lowered TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $9.00.

TuHURA Biosciences Stock Performance

HURA opened at $2.26 on Monday. TuHURA Biosciences has a 1-year low of $0.41 and a 1-year high of $3.90. The stock has a market capitalization of $143.92 million, a price-to-earnings ratio of -3.70 and a beta of 0.01. The business has a 50 day moving average of $2.26 and a 200-day moving average of $1.60.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01).

Hedge Funds Weigh In On TuHURA Biosciences

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in TuHURA Biosciences by 1.6% in the third quarter. Vanguard Group Inc. now owns 2,269,666 shares of the company’s stock valued at $5,629,000 after acquiring an additional 35,426 shares during the last quarter. Geode Capital Management LLC raised its position in shares of TuHURA Biosciences by 6.4% during the fourth quarter. Geode Capital Management LLC now owns 662,481 shares of the company’s stock worth $501,000 after purchasing an additional 39,710 shares during the period. State Street Corp raised its position in shares of TuHURA Biosciences by 4.9% during the fourth quarter. State Street Corp now owns 289,133 shares of the company’s stock worth $219,000 after purchasing an additional 13,594 shares during the period. Apollon Wealth Management LLC raised its position in TuHURA Biosciences by 17.7% in the 1st quarter. Apollon Wealth Management LLC now owns 158,010 shares of the company’s stock valued at $283,000 after buying an additional 23,717 shares during the last quarter. Finally, Cetera Investment Advisers acquired a new stake in TuHURA Biosciences in the 1st quarter valued at approximately $251,000. Institutional investors own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.